The board meeting for UroGen Pharma Ltd is scheduled for today, for the purpose of H.C. Wainwright 27(th) Annual Global Healthcare ConferenceSee details
UroGen Pharma Ltd has a share price target of US$ 34, revenue growth forecast of 36.8%, and profit growth estimate of -14.9% for FY25, based on top 7 analyst calls.